Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acs.jmedchem.0c00776 http://scihub22266oqcxt.onion/10.1021/acs.jmedchem.0c00776 32692176!ä!32692176 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Chem 2020 ; 63 (22): 13258-13265 Nephropedia Template TP {{tp|p=32692176|t=2020. Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?|pdf=|usr=}}{{32692176}} gab.com Text Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS JO: J Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=32692176 #FOAvip Cathepsin C (CatC) is a cysteine dipeptidyl aminopeptidase that activates most of tissue-degrading elastase-related serine proteases. Thus, CatC appears as a potential therapeutic target to impair protease-driven tissue degradation in chronic inflammatory and autoimmune diseases. A depletion of proinflammatory elastase-related proteases in neutrophils is observed in patients with CatC deficiency (Papillon-Lefevre syndrome). To address and counterbalance unwanted effects of elastase-related proteases, chemical inhibitors of CatC are being evaluated in preclinical and clinical trials. Neutrophils may contribute to the diffuse alveolar inflammation seen in acute respiratory distress syndrome (ARDS) which is currently a growing challenge for intensive care units due to the outbreak of the COVID-19 pandemic. Elimination of elastase-related neutrophil proteases may reduce the progression of lung injury in these patients. Pharmacological CatC inhibition could be a potential therapeutic strategy to prevent the irreversible pulmonary failure threatening the life of COVID-19 patients. Twit Text FOAVip Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS ????J Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=32692176 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32692176 #FOAvip English Wikipedia <ref>{{Cite pmid|32692176}}</ref> Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS? #MMPMID32692176 Korkmaz B; Lesner A; Marchand-Adam S; Moss C; Jenne DE J Med Chem 2020[Nov]; 63 (22): 13258-13265 PMID32692176show ga Cathepsin C (CatC) is a cysteine dipeptidyl aminopeptidase that activates most of tissue-degrading elastase-related serine proteases. Thus, CatC appears as a potential therapeutic target to impair protease-driven tissue degradation in chronic inflammatory and autoimmune diseases. A depletion of proinflammatory elastase-related proteases in neutrophils is observed in patients with CatC deficiency (Papillon-Lefevre syndrome). To address and counterbalance unwanted effects of elastase-related proteases, chemical inhibitors of CatC are being evaluated in preclinical and clinical trials. Neutrophils may contribute to the diffuse alveolar inflammation seen in acute respiratory distress syndrome (ARDS) which is currently a growing challenge for intensive care units due to the outbreak of the COVID-19 pandemic. Elimination of elastase-related neutrophil proteases may reduce the progression of lung injury in these patients. Pharmacological CatC inhibition could be a potential therapeutic strategy to prevent the irreversible pulmonary failure threatening the life of COVID-19 patients. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |COVID-19/enzymology[MESH] |Cathepsin C/*antagonists & inhibitors[MESH] |Cell Line, Tumor[MESH] |Clinical Trials as Topic[MESH] |Drug Evaluation, Preclinical[MESH] |Humans[MESH] |Lung/*drug effects/immunology[MESH] |Neutrophil Infiltration/drug effects[MESH] |Neutrophils/drug effects/enzymology[MESH] |Protease Inhibitors/chemistry/*pharmacology/therapeutic use[MESH]Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and(epmc).pdf DeepDyve Pubget Overpricing